Trials / Unknown
UnknownNCT05328960
The Pandemic's Effect on Diagnosis and Treatment of Rectal Cancer
An Analysis of Covid-19 Effect on Patients With Colorectal Cancer - Follow-up Regarding Tumour Stage, Neoadjuvant Treatment, Delay and Long-term Survival
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 8,000 (estimated)
- Sponsor
- Sahlgrenska University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Colorectal cancer is common with an annual prevalence of 6000. The majority can be cured and the five year survival rate is over 60%. In december 2019 reports came in about SARS-Cov-2, which later was named Covid-19. The World Health Organization classified it as a pandemic in March 2020. In Sweden the number of patients with Covid-19 increased mainly in the urban areas in March 2020. Care for patients with other diseases were affected and local changes from guidelines were adopted. In some regions and countries the indications for adjuvant and neoadjuvant treatment for colorectal cancer were somewhat changed. The number of patients diagnosed with colorectal cancer also decreased, as well as other types of cancer. The true effect on outcome with a delayed diagnosis remains unknown. The aim of this study is to evaluate the effects of the Covid-19 pandemic on the diagnosis, treatment and survival of patients with colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Diagnosed during or not during the pandemic | We will create a group of patients that are diagnosed before and after the pandemic and one group diagnosed during the pandemic |
Timeline
- Start date
- 2022-02-15
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
- First posted
- 2022-04-14
- Last updated
- 2023-12-08
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT05328960. Inclusion in this directory is not an endorsement.